TPCW
ROIV icon

TD Private Client Wealth’s Roivant Sciences ROIV Stock Holding History

TD Private Client Wealth’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.7K Sell
698
-130
-16% -$3.84K ﹤0.01% 1010
2026
Q1 		$22.9K Buy
828
+1
+0.1% +$26 ﹤0.01% 984
2025
Q4 		$17.9K Buy
827
+7
+0.9% +$138 ﹤0.01% 1023
2025
Q3 		$12.4K Hold
820
– – ﹤0.01% 1053
2025
Q2 		$9.24K Buy
820
+366
+81% +$3.97K ﹤0.01% 1059
2025
Q1 		$4.58K Buy
+454
New +$4.91K ﹤0.01% 1090
2024
Q4 		– Sell
-454
Closed -$5.24K – 1342
2024
Q3 		$5.24K Hold
454
– – ﹤0.01% 1111
2024
Q2 		$4.8K Buy
454
+76
+20% +$833 ﹤0.01% 1092
2024
Q1 		$3.98K Sell
378
-72
-16% -$776 ﹤0.01% 1101
2023
Q4 		$5.05K Sell
450
-191
-30% -$1.86K ﹤0.01% 1114
2023
Q3 		$7.49K Sell
641
-1,168
-65% -$13.2K ﹤0.01% 1071
2023
Q2 		$18.2K Buy
+1,809
New +$16.2K ﹤0.01% 961

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

TD Private Client Wealth's ROIV Position: Q2 2026 in Review

TD Private Client Wealth reduced its Roivant Sciences (ROIV) stake by 16% in Q2 2026, selling an estimated $3.84K and leaving 698 shares worth $24.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1010.

TD Private Client Wealth first reported a position in ROIV in Q2 2023 and has held it in 12 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • TD Private Client Wealth held 698 shares of Roivant Sciences worth $24.7K as of Q2 2026.
  • TD Private Client Wealth sold 130 Roivant Sciences shares in Q2 2026, an estimated $3.84K.
  • Roivant Sciences made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1010 holding.
  • TD Private Client Wealth first reported a position in Roivant Sciences in Q2 2023 and has held it in 12 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.